Sjögren-Larsson syndrome: a complex metabolic disease with a distinctive ocular phenotype

References

• Sjögren T, Larsson T. Oligophrenia in combination with congenital ichthyosis and spastic disorders. Acta Psychiatr Neurol Scand. 1957;32:1–113.
   PubMedGoogle Scholar
• Theile U. Sjögren-Larsson syndrome. Oligophrenia–ichthyosis–di-tetraplegia. Humangenetik. 1974;22:91–118.
   PubMedGoogle Scholar
• Jagell S, Polland W, Sandgren O. Specific changes in the fundus typical for the Sjögren-Larsson syndrome. An ophthalmological study of 35 patients. Acta Ophthalmol (Copenh). 1980;58:321–30. doi:10.1111/j.1755-3768.1980.tb05730.x.
   PubMed Web of Science ®Google Scholar
• Rizzo WB, Dammann AL, Craft DA. Sjögren-Larsson syndrome. Impaired fatty alcohol oxidation in cultured fibroblasts due to deficient fatty alcohol: nicotinamideadenine dinucleotide oxidoreductase activity. J Clin Invest. 1988;81:738–44. doi:10.1172/JCI113379.
   PubMed Web of Science ®Google Scholar
• Rizzo WB, Craft DA. Sjögren-Larsson syndrome. Deficient activity of the fatty aldehyde dehydrogenase component of fatty alcohol: NAD+oxidoreductase in cultured fibroblasts. J Clin Invest. 1991;88:1643–48. doi:10.1172/JCI115478.
   PubMed Web of Science ®Google Scholar
• De Laurenzi V, Rogers GR, Hamrock DJ, Marekov LN, Steinert PM, Compton JG, Markova N, Rizzo WB. Sjögren-Larsson syndrome is caused by mutations in the fatty aldehyde dehydrogenase gene. Nat Genet. 1996;12:52–57. doi:10.1038/ng0196-52.
   PubMed Web of Science ®Google Scholar
• Rizzo WB. Genetics and prospective therapeutic targets for Sjögren-Larsson syndrome. Expert Opin Orphan Drugs. 2016;4:395–406. doi:10.1517/21678707.2016.1154453.
   PubMed Web of Science ®Google Scholar
• Jagell S, Gustavson KH, Holmgren G. Sjögren-Larsson syndrome in Sweden. A clinical, genetic and epidemiological study. Clin Genet. 1981;19:233–56. doi:10.1111/j.1399-0004.1981.tb00704.x.
   PubMed Web of Science ®Google Scholar
• Jagell S, Lidén S. Ichthyosis in the Sjögren-Larsson syndrome. Clin Genet. 1982;21:243–52. doi:10.1111/j.1399-0004.1982.tb00758.x.
   PubMed Web of Science ®Google Scholar
• Hofer PA, Jagell S. Sjögren-Larsson syndrome: a dermato-histopathological study. J Cutan Pathol. 1982;9:360–76.
   PubMed Web of Science ®Google Scholar
• Rizzo WB, S’Aulis D, Jennings MA, Crumrine DA, Williams ML, Elias PM. Ichthyosis in Sjögren-Larsson syndrome reflects defective barrier function due to abnormal lamellar body structure and secretion. Arch Dermatol Res. 2010;302:443–51. doi:10.1007/s00403-009-1022-y.
   PubMed Web of Science ®Google Scholar
• Fuijkschot J, Theelen T, Seyger MMB, van der Graaf M, de Groot IJM, Wevers RA, Wanders RJA, Waterham HR, Willemsen MAAP. Sjögren-Larsson syndrome in clinical practice. J Inherit Metab Dis. 2012;35:955–62. doi:10.1007/s10545-012-9518-6.
   PubMed Web of Science ®Google Scholar
• Willemsen MA, IJlst L, Steijlen PM, Rotteveel PM, de Jong JJ, van Domburg PH, Mayatepek E, Gabreëls FB, Wanders RJ. Clinical, biochemical and molecular genetic characteristics of 19 patients with the Sjögren-Larsson syndrome. Brain. 2001;124:1426–37. doi:10.1093/brain/124.7.1426.
   PubMed Web of Science ®Google Scholar
• Gånemo A, Jagell S, Vahlquist A. Sjögren-Larsson syndrome: a study of clinical symptoms and dermatological treatment in 34 Swedish patients. Acta Derm Venereol. 2009;89:68–73. doi:10.2340/00015555-0561.
   PubMed Web of Science ®Google Scholar
• Jagell S, Heijbel J. Sjögren-Larsson syndrome: physical and neurological features. A survey of 35 patients. Helv Paediatr Acta. 1982;37:519–30.
   PubMedGoogle Scholar
• Papathemeli D, Mataftsi A, Patsatsi A, Sotiriadis D, Samouilidou M, Chondromatidou S, Evangeliou A. Atypical presentation of Sjögren-Larsson syndrome. Case Rep Pediatr. 2017;2017:7981750.
   PubMedGoogle Scholar
• Verhoog J, Fuijkschot J, Willemsen M, Ketelaar M, Rotteveel J, Gorter JW. Sjögren-Larsson syndrome: motor performance and everyday functioning in 17 patients. Dev Med Child Neurol. 2008;50:38–43. doi:10.1111/j.1469-8749.2007.02013.x.
   PubMed Web of Science ®Google Scholar
• Willemsen MAAP, Van Der Graaf M, Van Der Knaap MS, Heerschap A, van Domburg PHMF, Gabreëls FJM, Rotteveel JJ. MR imaging and proton MR spectroscopic studies in Sjögren-Larsson syndrome: characterization of the leukoencephalopathy. AJNR Am J Neuroradiol. 2004;25:649–57.
   PubMed Web of Science ®Google Scholar
• Mano T, Ono J, Kaminaga T, Imai K, Sakurai K, Harada K, Nagai T, Rizzo WB, Okada S. Proton MR spectroscopy of Sjögren-Larsson’s syndrome. AJNR Am J Neuroradiol. 1999;20:1671–73.
   PubMed Web of Science ®Google Scholar
• Rizzo WB. Sjögren-Larsson syndrome: fatty aldehyde dehydrogenase deficiency. In: Scriver CR, Beaudet AL, Valle D, Sly WS, editors. The metabolic & molecular bases of inherited disease. New York: McGraw-Hill; 2001. p. 2239–58.
   Google Scholar
• Lossos A, Khoury M, Rizzo WB, Gomori JM, Banin E, Zlotogorski A, Jaber S, Abransky O, Argov Z, Rosemann H. Phenotypic variability among adult siblings with Sjögren-Larsson syndrome. Arch Neurol. 2006;63:278–80. doi:10.1001/archneur.63.2.278.
   PubMedGoogle Scholar
• Kariminejad A, Barzgar M, Bozorgmehr B, Keshavarz E, Kariminejad MH, S’Aulis D, Rizzo WB. Novel mutations and a severe neurological phenotype in Sjögren-Larsson syndrome patients from Iran. Eur J Med Genet. 2018;61:139–44. doi:10.1016/j.ejmg.2017.11.006.
   PubMed Web of Science ®Google Scholar
• Cho KH, Shim SH, Jung Y, Sung SR, Kim M. Neurodegeneration in an adolescent with Sjögren-Larsson syndrome: a decade-long follow-up case report. BMC Med Genet. 2018;19:152. doi:10.1186/s12881-018-0663-0.
   PubMed Web of Science ®Google Scholar
• Black WJ, Stagos D, Marchitti SA, Nebert DW, Tipton KF, Bairoch A, Vasiliou V. Human aldehyde dehydrogenase genes: alternatively spliced transcriptional variants and their suggested nomenclature. Pharmacogenet Genomics. 2009;19:893–902. doi:10.1097/FPC.0b013e3283329023.
   PubMed Web of Science ®Google Scholar
• Lin Z, Carney G, Rizzo WB. Genomic organization, expression, and alternate splicing of the mouse fatty aldehyde dehydrogenase gene. Mol Genet Metab. 2000;71:496–505. doi:10.1006/mgme.2000.3084.
   PubMed Web of Science ®Google Scholar
• Naganuma T, Takagi S, Kanetake T, Kitamura T, Hattori S, Miyakawa T, Sassa T, Kihara A. Disruption of the Sjögren-Larsson syndrome gene Aldh3a2 in mice increases keratinocyte growth and retards skin barrier recovery. J Biol Chem. 2016;291:11676–88. doi:10.1074/jbc.M116.714030.
   PubMed Web of Science ®Google Scholar
• Cai H, Fields MA, Hoshino R, Priore LV. Effects of aging and anatomic location on gene expression in human retina. Front Aging Neurosci. 2012;4:8. doi:10.3389/fnagi.2012.00008.
   PubMed Web of Science ®Google Scholar
• Kelson TL, Secor McVoy JR, Rizzo WB. Human liver fatty aldehyde dehydrogenase: microsomal localization, purification, and biochemical characterization. Biochim Biophys Acta. 1997;1335:99–110. doi:10.1016/s0304-4165(96)00126-2.
   PubMed Web of Science ®Google Scholar
• Lloyd MD, Boardman KDE, Smith A, van Den Brink DM, Wanders RJA, Threadgill MD. Characterisation of recombinant human fatty aldehyde dehydrogenase: implications for Sjögren-Larsson syndrome. J Enzyme Inhib Med Chem. 2007;22:584–90. doi:10.1080/14756360701425360.
   PubMed Web of Science ®Google Scholar
• Roullet J-B SR, Rizzo W. Impaired isoprenoid metabolism in Sjögren-Larsson syndrome. J Inherit Metab Dis. 2006;29:A49.
   Web of Science ®Google Scholar
• Keller MA, Zander U, Fuchs JE, Kreutz C, Watschinger K, Mueller T, Golderer G, Liedl KR, Ralser M, Kräutler B, et al. A gatekeeper helix determines the substrate specificity of Sjögren-Larsson syndrome enzyme fatty aldehyde dehydrogenase. Nat Commun. 2014;5:4439.
   PubMed Web of Science ®Google Scholar
• Ichihara K, Kusunose E, Noda Y, Kusunose M. Some properties of the fatty alcohol oxidation system and reconstitution of microsomal oxidation activity in intestinal mucosa. Biochim Biophys Acta. 1986;878:412–18. doi:10.1016/0005-2760(86)90250-x.
   PubMed Web of Science ®Google Scholar
• Rizzo WB. Sjögren-Larsson syndrome: molecular genetics and biochemical pathogenesis of fatty aldehyde dehydrogenase deficiency. Mol Genet Metab. 2007;90:1–9. doi:10.1016/j.ymgme.2006.08.006.
   PubMed Web of Science ®Google Scholar
• Rizzo WB. Fatty aldehyde and fatty alcohol metabolism: review and importance for epidermal structure and function. Biochim Biophys Acta. 2014;1841:377–89. doi:10.1016/j.bbalip.2013.09.001.
   PubMed Web of Science ®Google Scholar
• Nakahara K, Ohkuni A, Kitamura T, Abe K, Naganuma T, Ohno Y, Zoeller RA, Kihara A. The Sjögren-Larsson syndrome gene encodes a hexadecenal dehydrogenase of the sphingosine 1-phosphate degradation pathway. Mol Cell. 2012;46:461–71. doi:10.1016/j.molcel.2012.04.033.
   PubMed Web of Science ®Google Scholar
• Verhoeven NM, Jakobs C, Carney G, Somers MP, Wanders RJ, Rizzo WB. Involvement of microsomal fatty aldehyde dehydrogenase in the alpha-oxidation of phytanic acid. FEBS Lett. 1998;429:225–28. doi:10.1016/s0014-5793(98)00574-2.
   PubMed Web of Science ®Google Scholar
• Jansen GA, van Den Brink DM, Ofman R, Draghici O, Dacremont G, Wanders RJ. Identification of pristanal dehydrogenase activity in peroxisomes: conclusive evidence that the complete phytanic acid alpha-oxidation pathway is localized in peroxisomes. Biochem Biophys Res Commun. 2001;283:674–79. doi:10.1006/bbrc.2001.4835.
   PubMed Web of Science ®Google Scholar
• Willemsen MA, Rotteveel JJ, de Jong JGN, Wanders RJA, IJlst L, Hoffmann GF, Mayatepek E. Defective metabolism of leukotriene B4 in the Sjögren-Larsson syndrome. J Neurol Sci. 2001;183:61–67. doi:10.1016/s0022-510x(00)00474-3.
   PubMed Web of Science ®Google Scholar
• Rizzo WB, Heinz E, Simon M, Craft DA. Microsomal fatty aldehyde dehydrogenase catalyzes the oxidation of aliphatic aldehyde derived from ether glycerolipid catabolism: implications for Sjögren-Larsson syndrome. Biochim Biophys Acta. 2000;1535:1–9. doi:10.1016/s0925-4439(00)00077-6.
   PubMed Web of Science ®Google Scholar
• Demozay D, Rocchi S, Mas J-C, Grillo S, Pirola L, Chavey C, Van Obberghen E. Fatty aldehyde dehydrogenase: potential role in oxidative stress protection and regulation of its gene expression by insulin. J Biol Chem. 2004;279:6261–70. doi:10.1074/jbc.M312062200.
   PubMed Web of Science ®Google Scholar
• Demozay D, Mas J-C, Rocchi S, Van Obberghen E. FALDH reverses the deleterious action of oxidative stress induced by lipid peroxidation product 4-hydroxynonenal on insulin signaling in 3T3-L1 adipocytes. Diabetes. 2008;57:1216–26. doi:10.2337/db07-0389.
   PubMed Web of Science ®Google Scholar
• Rogers GR, Markova NG, De Laurenzi V, Rizzo WB, Compton JG. Genomic organization and expression of the human fatty aldehyde dehydrogenase gene (FALDH). Genomics. 1997;39:127–35. doi:10.1006/geno.1996.4501.
   PubMed Web of Science ®Google Scholar
• Ashibe B, Hirai T, Higashi K, Sekimizu K, Motojima K. Dual subcellular localization in the endoplasmic reticulum and peroxisomes and a vital role in protecting against oxidative stress of fatty aldehyde dehydrogenase are achieved by alternative splicing. J Biol Chem. 2007;282:20763–73. doi:10.1074/jbc.M611853200.
   PubMed Web of Science ®Google Scholar
• Weustenfeld M, Eidelpes R, Schmuth M, Rizzo WB, Zschocke J, Keller MA. Genotype and phenotype variability in Sjögren-Larsson syndrome. Hum Mutat. 2019;40:177–86. doi:10.1002/humu.23679.
   PubMed Web of Science ®Google Scholar
• Rizzo WB, Carney G, Lin Z. The molecular basis of Sjögren-Larsson syndrome: mutation analysis of the fatty aldehyde dehydrogenase gene. Am J Hum Genet. 1999;65:1547–60. doi:10.1086/302681.
   PubMed Web of Science ®Google Scholar
• Rizzo WB, Carney G. Sjögren-Larsson syndrome: diversity of mutations and polymorphisms in the fatty aldehyde dehydrogenase gene (ALDH3A2). Hum Mutat. 2005;26:1–10. doi:10.1002/humu.20181.
   PubMed Web of Science ®Google Scholar
• Engelstad H, Carney G, S’aulis D, Rise J, Sanger WG, Rudd MK, Richard G, Carr CW, Abdul-Rahman OA, Rizzo WB. Large contiguous gene deletions in Sjögren-Larsson syndrome. Mol Genet Metab. 2011;104:356–61. doi:10.1016/j.ymgme.2011.05.015.
   PubMed Web of Science ®Google Scholar
• Rizzo WB, Carney G, De Laurenzi V. A common deletion mutation in European patients with Sjögren-Larsson syndrome. Biochem Mol Med. 1997;62:178–81.
   PubMedGoogle Scholar
• Sillén A, Anton-Lamprecht I, Braun-Quentin C, Kraus CS, Sayli BS, Ayuso C, Jagell S, Küster W, Wadelius C. Spectrum of mutations and sequence variants in the FALDH gene in patients with Sjögren-Larsson syndrome. Hum Mutat. 1998;12:377–84. doi:10.1002/(SICI)1098-1004(1998)12:6<377::AID-HUMU3>3.0.CO;2-I.
   PubMed Web of Science ®Google Scholar
• Kraus C, Braun-Quentin C, Ballhausen WG, Pfeiffer RA. RNA-based mutation screening in German families with Sjögren-Larsson syndrome. Eur J Hum Genet. 2000;8:299–306. doi:10.1038/sj.ejhg.5200453.
   PubMed Web of Science ®Google Scholar
• Auada MP, Puzzi MB, Cintra ML, Steiner CE, Alexandrino F, Sartorato EL, Aguiar TS, Azulay RD, Carney G, Rizzo WB. Sjögren-Larsson syndrome in Brazil is caused by a common c.1108-1G>C splice-site mutation in the ALDH3A2 gene. Br J Dermatol. 2006;154:770–73. doi:10.1111/j.1365-2133.2006.07135.x.
   PubMed Web of Science ®Google Scholar
• Nigro JF, Rizzo WB, Esterly NB. Redefining the Sjögren-Larsson syndrome: atypical findings in three siblings and implications regarding diagnosis. J Am Acad Dermatol. 1996;35:678–84. doi:10.1016/s0190-9622(96)90720-3.
   PubMed Web of Science ®Google Scholar
• Losito L, Gennaro L, De Rinaldis M, Cacudi M, Trabacca A. Sjögren-Larsson syndrome: phenotypic variability in two brothers with a neurocutaneous disorder. Acta Neurol Belg. 2012;112:205–08. doi:10.1007/s13760-012-0035-z.
   PubMed Web of Science ®Google Scholar
• Jack LS, Benson C, Sadiq MA, Rizzo WB, Margalit E. Segmentation of retinal layers in Sjögren-Larsson syndrome. Ophthalmology. 2015;122:1730–32. doi:10.1016/j.ophtha.2015.02.003.
   PubMed Web of Science ®Google Scholar
• Fuijkschot J, Cruysberg JRM, Willemsen MAAP, Keunen JEE, Theelen T. Subclinical changes in the juvenile crystalline macular dystrophy in Sjögren-Larsson syndrome detected by optical coherence tomography. Ophthalmology. 2008;115:870–75. doi:10.1016/j.ophtha.2007.05.063.
   PubMed Web of Science ®Google Scholar
• Willemsen MA, Cruysberg JR, Rotteveel JJ, Aandekerk AL, Van Domburg PH, Deutman AF. Juvenile macular dystrophy associated with deficient activity of fatty aldehyde dehydrogenase in Sjögren-Larsson syndrome. Am J Ophthalmol. 2000;130:782–89. doi:10.1016/s0002-9394(00)00576-6.
   PubMed Web of Science ®Google Scholar
• Bhallil S, Chraibi F, Andalloussi IB, Tahri H. Optical coherence tomography aspect of crystalline macular dystrophy in Sjögren-Larsson syndrome. Int Ophthalmol. 2012;32:495–98. doi:10.1007/s10792-012-9590-9.
   PubMedGoogle Scholar
• Theelen T, Cruysberg JR, Willemsen MA. Macular fibrosis complicating macular pigment deficient maculopathy in Sjögren-Larsson syndrome. Acta Ophthalmol. 2016;94:e663–e664. doi:10.1111/aos.13042.
   PubMed Web of Science ®Google Scholar
• Wallis K, Kalushiner A. Oligophrenia in combination with congenital ichthyosis, spastic disorders and macular degeneration (Sjögren-Larsson syndrome). Ann Paediatr. 1960;194:114–24.
   PubMedGoogle Scholar
• Zaleski WA. Congenital ichthyosis, mental retardation and spasticity (Sjögren-Larsson syndrome). Can Med Assoc J. 1962;86:951–54.
   PubMed Web of Science ®Google Scholar
• Gilbert WR, Smith JL, Nyhan WL. The Sjögren-Larsson syndrome. Arch Ophthalmol. 1968;80:308–16. doi:10.1001/archopht.1968.00980050310003.
   PubMedGoogle Scholar
• Srinivas SM, Raju KV, Hiremagalore R. Sjögren-Larsson syndrome: A study of clinical symptoms in six children. Indian Dermatol Online J. 2014;5:185–88. doi:10.4103/2229-5178.131099.
   PubMedGoogle Scholar
• Jean-François E, Low JY, Gonzales CR, Sarraf D. Sjögren-Larsson syndrome and crystalline maculopathy associated with a novel mutation. Arch Ophthalmol. 2007;125:1582–83. doi:10.1001/archopht.125.11.1582.
   PubMedGoogle Scholar
• Isaac DLC, Queiroz GHM, Feres CC, Avila M. Macular crystalline dystrophy in Sjögren-Larsson syndrome: case report. Arq Bras Oftalmol. 2009;72:239–42.
   PubMed Web of Science ®Google Scholar
• Loukil I, Naija O, Hachicha F. Optical coherence tomography in Sjögren-Larsson syndrome diagnosis. Bull Soc Belge Ophtalmol. 2012;320:11–15.
   PubMedGoogle Scholar
• Burgueño-Montañés C, García-Fernández M, Colunga-Cueva M, García-López A. Sjögren-Larsson syndrome: optical coherence tomography and a novel mutation. Arch Soc Esp Oftalmol. 2014;89:504–07. doi:10.1016/j.oftal.2013.11.010.
   PubMedGoogle Scholar
• Kovach JL. Late-stage Sjögren-Larsson syndrome maculopathy imaged with OCT angiography. Ophthalmic Surg Lasers Imaging Retina. 2018;49:e78–e82. doi:10.3928/23258160-20180907-11.
   PubMed Web of Science ®Google Scholar
• Kovach JL, Isildak H, Sarraf D. Crystalline retinopathy: Unifying pathogenic pathways of disease. Surv Ophthalmol. 2019;64:1–29. doi:10.1016/j.survophthal.2018.08.001.
   PubMed Web of Science ®Google Scholar
• Nanda T, Kovach JL. Ophthalmic findings in late stage Sjögren-Larsson syndrome. Retin Cases Brief Rep. 2017. doi:10.1097/ICB.0000000000000583.
   Google Scholar
• Kirschfeld K. Carotenoid pigments: their possible role in protecting against photooxidation in eyes and photoreceptor cells. Proc R Soc Lond B Biol Sci. 1982;216:71–85. doi:10.1098/rspb.1982.0061.
   PubMed Web of Science ®Google Scholar
• Stringham JM, Garcia PV, Smith PA, Heirs PL, McLin LN, Kuyk TK, Foutch BK. Macular pigment and visual performance in low-light conditions. Invest Ophthalmol Vis Sci. 2015;56:2459–68. doi:10.1167/iovs.14-15716.
   PubMed Web of Science ®Google Scholar
• van der Veen RLP, Fuijkschot J, Willemsen MAAP, Cruysberg JRM, Berendschot TTJM, Theelen T. Patients with Sjögren-Larsson syndrome lack macular pigment. Ophthalmology. 2010;117:966–71. doi:10.1016/j.ophtha.2009.10.019.
   PubMed Web of Science ®Google Scholar
• Theelen T, Berendschot TTJM, Klevering BJ, Fuijkschot J, Hoyng CB, Willemsen MAAP. Multimodal imaging of the macula in hereditary and acquired lack of macular pigment. Acta Ophthalmol. 2014;92:138–42. doi:10.1111/aos.12092.
   PubMed Web of Science ®Google Scholar
• Schmitz-Valckenberg S, Holz FG, Bird AC, Spaide RF. Fundus autofluorescence imaging: review and perspectives. Retina. 2008;28:385–409. doi:10.1097/IAE.0b013e318164a907.
   PubMed Web of Science ®Google Scholar
• Mirshahi A, Piri N. Fundus autofluorescence changes in two cases of Sjögren-Larsson syndrome. Int Ophthalmol. 2009;29:541–45. doi:10.1007/s10792-008-9264-9.
   PubMedGoogle Scholar
• Sanabria MR, Coco RM. Sjögren-Larsson syndrome. Ophthalmology. 2011;118:2101–02. doi:10.1016/j.ophtha.2011.07.015.
   PubMed Web of Science ®Google Scholar
• Nilsson SE, Jagell S. Lipofuscin and melanin content of the retinal pigment epithelium in a case of Sjögren-Larsson syndrome. Br J Ophthalmol. 1987;71:224–26. doi:10.1136/bjo.71.3.224.
   PubMed Web of Science ®Google Scholar
• Sharma P, Chaudhuri Z, Raina UK, Ghosh B, Sethi S. Abnormal ocular electrophysiology in Sjögren-Larsson syndrome. J Pediatr Ophthalmol Strabismus. 2009;46:42–44.
   PubMed Web of Science ®Google Scholar
• Roy U, Das U, Pandit A, Debnath A. Sjögren-Larsson syndrome: a rare disease of the skin and central nervous system. BMJ Case Rep. 2016;2016. doi:10.1136/bcr-2016.
   Google Scholar
• Diaz LZ, Browning JC, Smidt AC, Rizzo WB, Levy ML. Complications of ichthyosis beyond the skin. Dermatol Ther. 2013;26:39–45. doi:10.1111/j.1529-8019.2012.01517.x.
   PubMed Web of Science ®Google Scholar
• McLennan JE, Gilles FH, Robb RM. Neuropathological correlation in Sjögren-Larsson syndrome. Oligophrenia, ichthyosis and spasticity. Brain. 1974;97:693–708. doi:10.1093/brain/97.1.693.
   PubMed Web of Science ®Google Scholar
• Sylvester PE. Pathological findings in Sjögren-Larsson syndrome. J Ment Defic Res. 1969;13:267–75.
   PubMedGoogle Scholar
• Baar HS, Galindo J. Pathology of the Sjögren-Larsson syndrome. J Maine Med Assoc. 1965;56:223–26.
   PubMedGoogle Scholar
• Silva CA, Saraiva A, Gonçalves V, de Sousa G, Martins R, Cruz C. Pathological findings in one of two siblings with Sjögren-Larsson syndrome. Eur Neurol. 1980;19:166–70. doi:10.1159/000115142.
   PubMed Web of Science ®Google Scholar
• James PF, Zoeller RA. Isolation of animal cell mutants defective in long-chain fatty aldehyde dehydrogenase. Sensitivity to fatty aldehydes and Schiff’s base modification of phospholipids: implications for Sjogren-Larsson syndrome. J Biol Chem. 1997;272:23532–39. doi:10.1074/jbc.272.38.23532.
   PubMed Web of Science ®Google Scholar
• Schumacher F, Neuber C, Finke H, Nieschalke K, Baesler J, Gulbins E, Kleuser B. The sphingosine 1-phosphate breakdown product, (2E)-hexadecenal, forms protein adducts and glutathione conjugates in vitro. J Lipid Res. 2017;58:1648–60. doi:10.1194/jlr.M076562.
   PubMed Web of Science ®Google Scholar
• Jarugumilli GK, Choi JR, Chan P, Yu M, Sun Y, Chen B, Niu J, DeRan M, Zheng B, Zoeller R, et al. Chemical probe to identify the cellular targets of the reactive lipid metabolite 2- trans-hexadecenal. ACS Chem Biol. 2018;13:1130–36.
   PubMed Web of Science ®Google Scholar
• Bernstein PS, Li B, Vachali PP, Gorusupudi A, Shyam R, Henriksen BS, Nolan JM. Lutein, zeaxanthin, and meso-zeaxanthin: The basic and clinical science underlying carotenoid-based nutritional interventions against ocular disease. Prog Retin Eye Res. 2016;50:34–66. doi:10.1016/j.preteyeres.2015.10.003.
   PubMed Web of Science ®Google Scholar
• Mares J. Lutein and zeaxanthin isomers in eye health and disease. Annu Rev Nutr. 2016;36:571–602. doi:10.1146/annurev-nutr-071715-051110.
   PubMed Web of Science ®Google Scholar
• Fiedor J, Burda K. Potential role of carotenoids as antioxidants in human health and disease. Nutrients. 2014;6:466–88. doi:10.3390/nu6020466.
   PubMed Web of Science ®Google Scholar
• Harrison EH, Dela Sena C, Eroglu A, Fleshman MK. The formation, occurrence, and function of β-apocarotenoids: β-carotene metabolites that may modulate nuclear receptor signaling. Am J Clin Nutr. 2012;96:1189S–92S. doi:10.3945/ajcn.112.034843.
   PubMed Web of Science ®Google Scholar
• Haug S, Braun-Falco M. Restoration of fatty aldehyde dehydrogenase deficiency in Sjögren-Larsson syndrome. Gene Ther. 2006;13:1021–26. doi:10.1038/sj.gt.3302743.
   PubMed Web of Science ®Google Scholar
• Kumar A, Byun H-S, Bittman R, Saba JD. The sphingolipid degradation product trans-2-hexadecenal induces cytoskeletal reorganization and apoptosis in a JNK-dependent manner. Cell Signal. 2011;23:1144–52. doi:10.1016/j.cellsig.2011.02.009.
   PubMed Web of Science ®Google Scholar
• Kalariya NM, Ramana KV, Srivastava SK, van Kuijk FJGM. Carotenoid derived aldehydes-induced oxidative stress causes apoptotic cell death in human retinal pigment epithelial cells. Exp Eye Res. 2008;86:70–80. doi:10.1016/j.exer.2007.09.010.
   PubMed Web of Science ®Google Scholar
• Rizzo WB, Craft DA. Sjögren-Larsson syndrome: accumulation of free fatty alcohols in cultured fibroblasts and plasma. J Lipid Res. 2000;41:1077–81.
   PubMed Web of Science ®Google Scholar
• Rizzo WB, Craft DA, Somer T, Carney G, Trafrova J, Simon M. Abnormal fatty alcohol metabolism in cultured keratinocytes from patients with Sjögren-Larsson syndrome. J Lipid Res. 2008;49:410–19. doi:10.1194/jlr.M700469-JLR200.
   PubMed Web of Science ®Google Scholar
• Franks NP, Lieb WR. Partitioning of long-chain alcohols into lipid bilayers: implications for mechanisms of general anesthesia. Proc Natl Acad Sci U S A. 1986;83:5116–20. doi:10.1073/pnas.83.14.5116.
   PubMed Web of Science ®Google Scholar
• Miller KW, Firestone LL, Alifimoff JK, Streicher P. Nonanesthetic alcohols dissolve in synaptic membranes without perturbing their lipids. Proc Natl Acad Sci U S A. 1989;86:1084–87. doi:10.1073/pnas.86.3.1084.
   PubMed Web of Science ®Google Scholar
• Artero Castro A, Lukovic D, Jendelova P, Erceg S. Concise review: human induced pluripotent stem cell models of retinitis pigmentosa. Stem Cells. 2018;36:474–81. doi:10.1002/stem.2783.
   PubMed Web of Science ®Google Scholar
• Rizzo WB, Jenkens SM, Boucher P. Recognition and diagnosis of neuro-ichthyotic syndromes. Semin Neurol. 2012;32:75–84. doi:10.1055/s-0032-1306390.
   PubMed Web of Science ®Google Scholar
• Kelson TL, Craft DA, Rizzo WB. Carrier detection for Sjögren-Larsson syndrome. J Inherit Metab Dis. 1992;15:105–11.
   PubMed Web of Science ®Google Scholar
• Marchette LD, Wang H, Li F, Babizhayev MA, Kasus-Jacobi A. Carcinine has 4-hydroxynonenal scavenging property and neuroprotective effect in mouse retina. Invest Ophthalmol Vis Sci. 2012;53:3572–83. doi:10.1167/iovs.11-9042.
   PubMed Web of Science ®Google Scholar
• Maeda A, Golczak M, Chen Y, Okano K, Kohno H, Shiose S, Ishikawa K, Harte W, Palczewska G, Maeda T, et al. Primary amines protect against retinal degeneration in mouse models of retinopathies. Nat Chem Biol. 2012;8:170–78.
   Web of Science ®Google Scholar
• Rizzo WB, Baley Z, S’Aulis D, Ergasheva N. Aldehyde trapping agent NS2 blocks formation of fatty aldehyde adducts with phosphatidylethanolamine and suggests potential therapeutic approach for Sjögren-Larsson syndrome. Mol Genet Metab. 2015;114:362.
   Web of Science ®Google Scholar
• Gloerich J, Ijlst L, Wanders RJA, Ferdinandusse S. Bezafibrate induces FALDH in human fibroblasts; implications for Sjögren-Larsson syndrome. Mol Genet Metab. 2006;89:111–15. doi:10.1016/j.ymgme.2006.05.009.
   PubMed Web of Science ®Google Scholar
• Takahashi VKL, Takiuti JT, Jauregui R, Tsang SH. Gene therapy in inherited retinal degenerative diseases, a review. Ophthalmic Genet. 2018;39:560–68. doi:10.1080/13816810.2018.1495745.
   PubMed Web of Science ®Google Scholar